title: A meta-analysis comparing the efficacy of entecavir and tenofovir for the treatment of chronic hepatitis B infection.
abstract: The efficacy of entecavir and tenofovir in patients with chronic hepatitis B virus (HBV) is inconsistent. To address this issue, we conducted a meta-analysis based on a current review of the literature addressing the efficacy and safety of entecavir and tenofovir. Electronic databases were searched through June 2014 for relevant clinical trials. We included 2 randomized controlled trials, 2 prospective cohort studies, and 7 case-control studies that included 1,656 patients. In the entecavir group, 842 of 992 were nucleos(t)ide-naïve chronic HBV patients, and in the tenofovir group 481 of 664 were nucleos(t)ide-naïve. The virological response to tenofovir was superior to entecavir (RR: 0.82; 95%CI: 0.72-0.93), especially in nucleos(t)ide-naïve chronic HBV patients at 48 weeks (RR: 0.78; 95%CI: 0.65-0.92). Additionally, there was no difference between entecavir and tenofovir for virological response at 24 weeks (RR: 0.87, 95%CI: 0.71-1.05). The alanine aminotransferase normalization rate, serological response, and adverse event rate were also not significantly different between entecavir and tenofovir at 24 or 48 weeks after treatment. These results suggest that tenofovir is a better choice to treat chronic HBV patients than entecavir as it is better able to suppress HBV viral load and has a similar safety profile.
authors.affiliation: Center of Clinical Pharmacology and Pharmacy Department, The Third Xiangya Hospital, Central South University, Changsha, China.|School of Pharmaceutical Science, Central South University, Changsha, China.
authors.forename: Shan-Ru
authors.initials: SR
authors.lastname: Zuo
authors.affiliation: Center of Clinical Pharmacology and Pharmacy Department, The Third Xiangya Hospital, Central South University, Changsha, China.
authors.forename: Xiao-Cong
authors.initials: XC
authors.lastname: Zuo
authors.affiliation: Center of Clinical Pharmacology and Pharmacy Department, The Third Xiangya Hospital, Central South University, Changsha, China.
authors.forename: Chun-Jiang
authors.initials: CJ
authors.lastname: Wang
authors.affiliation: Center of Clinical Pharmacology and Pharmacy Department, The Third Xiangya Hospital, Central South University, Changsha, China.|School of Pharmaceutical Science, Central South University, Changsha, China.
authors.forename: Yu-Tao
authors.initials: YT
authors.lastname: Ma
authors.affiliation: Department of Infection, The Third Xiangya Hospital, Central South University, Changsha, China.
authors.forename: Hao-Ye
authors.initials: HY
authors.lastname: Zhang
authors.affiliation: Center of Clinical Pharmacology and Pharmacy Department, The Third Xiangya Hospital, Central South University, Changsha, China.
authors.forename: Zuo-Jun
authors.initials: ZJ
authors.lastname: Li
authors.affiliation: Center of Clinical Pharmacology and Pharmacy Department, The Third Xiangya Hospital, Central South University, Changsha, China.
authors.forename: Li-Ying
authors.initials: LY
authors.lastname: Song
authors.affiliation: Center of Clinical Pharmacology and Pharmacy Department, The Third Xiangya Hospital, Central South University, Changsha, China.
authors.forename: Zhen-Zhen
authors.initials: ZZ
authors.lastname: Deng
authors.affiliation: Center of Clinical Pharmacology and Pharmacy Department, The Third Xiangya Hospital, Central South University, Changsha, China.
authors.forename: Shi-Kun
authors.initials: SK
authors.lastname: Liu
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D002986:Clinical Trials as Topic; D006147:Guanine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006515:Hepatitis B virus / Q000187:drug effects* / Q000254:growth & development; D019694:Hepatitis B, Chronic / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D016017:Odds Ratio; D018579:Patient Selection; D012307:Risk Factors; D000068698:Tenofovir / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; C413685:entecavir; D006147:Guanine; D000068698:Tenofovir
keywords: chronic hepatitis B; entecavir; meta-analysis; tenofovir